Patents Assigned to Upjohn
  • Azepino[4,5-b]pyrano[3,2-e]indoles
    Patent number: 6503899
    Abstract: The invention provides a compound of formula (I): wherein: R1-R5, m, n, p, and the bonds a and b represented by - - - have any of the values, specific values, or preferred values described in the specification; or a salt or solvate thereof. The invention also provides pharmaceutical compositions comprising such a compound, as well as intermediates and processes useful for preparing such a compound, and therapeutic methods including the administration of such a compound.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: January 7, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventor: Jian-min Fu
  • AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS
    Publication number: 20030004350
    Abstract: Novel 1H-pyrrolo[2,3-b]pyridines which are represented by formula (I): 1
    Type: Application
    Filed: October 2, 2001
    Publication date: January 2, 2003
    Applicant: PHARMACIA & UPJOHN
    Inventors: Antonio Longo, Maria Gabriella Brasca, Paolo Orsini, Gabriella Traquandi, Valeria Pittala, Anna Vulpetti, Mario Varasi, Paolo Pevarello
  • Drug combinations
    Patent number: 6500827
    Abstract: This patent application describes a new combination treatment of selective, noradrenaline-reuptake inhibitors (NARI) and specifically, reboxetine, and pindolol to provide rapid relief to patients suffering from depression, general anxiety, attention deficit hyperactivity disorder (ADHD), anxiety disorders such as obsessive compulsive disorders (OCD), panic disorders (PD), social phobia (SD) and the like.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: December 31, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventor: Duncan Paul Taylor
  • Aspartyl protease 2 (Asp2) antisense oligonucleotides
    Patent number: 6500667
    Abstract: The present invention provides the enzyme and enzymatic procedures for cleaving the &bgr; secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
    Type: Grant
    Filed: April 18, 2000
    Date of Patent: December 31, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
  • 8-hydroxy-7-substituted quinolines as anti-viral agents
    Patent number: 6500842
    Abstract: The present invention provides for 8-hydroxy-7-substituted quinoline compounds such as formula IA These compounds are useful as anti-viral agents. Specifically, these compounds have anti-viral activity against the herpes virus, cytomegalovirus (CMV). Many of these compounds are also active against other herpes viruses, such as the varicella zoster virus, the Epstein-Barr virus, the herpes simplex virus and the human herpes virus type 8 (HHV-8).
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: December 31, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Valerie Ann Vaillancourt, Joseph Walter Strohbach, Olivier Bezencon, Suvit Thaisrivongs
  • Quinuclidine-substituted heteroaryl moieties for treatment of disease
    Patent number: 6500840
    Abstract: The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which &agr;7 is known to be involved.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: December 31, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Jason K. Myers, Bruce N. Rogers, Vincent E. Groppi, Jr., David W. Piotrowski, Alice L. Bodnar, Eric Jon Jacobsen, Jeffrey W. Corbett
  • Tetracyclic azepinoindole compounds
    Publication number: 20020198190
    Abstract: The present invention provides compounds of formula I: 1
    Type: Application
    Filed: June 17, 2002
    Publication date: December 26, 2002
    Applicant: PHARMACIA & UPJOHN COMPANY
    Inventors: Jackson B. Hester, Bruce N. Rogers, Eric Jon Jacobsen, Michael D. Ennis, Brad A. Acker, Susan L. Vander Velde, Kristine E. Frank
  • Methods for creating a compound library
    Publication number: 20020192707
    Abstract: A method for developing a library of compounds, the compound library, a method for identifying ligands for target molecules, and a method for identifying lead chemical templates, which, for example, can be used in drug discovery and design are provided. Certain embodiments of these methods include the use of NMR spectroscopy.
    Type: Application
    Filed: November 19, 2001
    Publication date: December 19, 2002
    Applicant: Pharmacia & Upjohn
    Inventors: Brian J. Stockman, Kathleen A. Farley
  • Intravaginal clindamycin ovule composition
    Patent number: 6495157
    Abstract: A highly storage-stable composition for vaginal administration of clindamycin is disclosed which is useful for the treatment of bacterial vaginosis. The composition is a vaginal suppository containing an antimicrobially effective amount of clindamycin dispersed in a Hard Fat NF suppository base. Hard Fat NF suppository bases provide a clindamycin product having long term storage stability while providing efficacy against bacterial vaginosis which is equivalent to clindamycin vaginal creams.
    Type: Grant
    Filed: July 20, 2000
    Date of Patent: December 17, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Lorraine Elisabeth Pena, Phil Bryan Bowman, Robert Shih-Liang Chao, Carolyn V. Pesheck
  • 4-oxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as antiviral agents
    Patent number: 6495683
    Abstract: The invention provides a compound of formula I: wherein R1, R2, R3, and R4 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of preventing or treating a herpesvirus infection using such compounds or salts.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: December 17, 2002
    Assignee: Pharmacia and Upjohn Company
    Inventor: Allen Scott
  • Stabilized aqueous suspensions for parenteral use
    Patent number: 6495534
    Abstract: A pharmaceutical aqueous suspension formulation for parenteral administration having substantially stabilized pH, comprising a biologically active compound and a pH controlling effective concentration of L-Methionine. Preferably, the biologically active compound is a steroidal compound, for instance exemestane, medroxyprogesterone acetate and estradiol cypionate or a combination of medroxyprogesterone acetate and estradiol cypionate.
    Type: Grant
    Filed: May 15, 2000
    Date of Patent: December 17, 2002
    Assignees: Pharmacia & Upjohn SpA, Pharmacia & Upjohn Company
    Inventors: Giuseppe Colombo, Alessandro Martini, Lloyd E. Fox
  • Quinuclidine-substituted heteroaryl moieties for treatment of disease
    Patent number: 6492385
    Abstract: The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which &agr;7 is known to be involved.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: December 10, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Jason K. Myers, Bruce N. Rogers, Vincent E. Groppi, Jr., David W. Piotrowski, Alice L. Bodnar, Eric Jon Jacobsen, Jeffrey W. Corbett
  • Quinuclidine-substituted aryl compounds for treatment of disease
    Patent number: 6492386
    Abstract: The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which &agr;7 is known to be involved.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: December 10, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Jason K. Myers, Vincent E. Groppi, Jr., David W. Piotrowski
  • Process to produce oxazolidinones
    Patent number: 6492555
    Abstract: The present invention includes a number of novel intermediates such as the (S)-secondary alcohol of formula (VIIIA) X2—CH2—C*H(OH)—CH2—NH—CO—RN  (VIIIA) and processes for production of pharmacologically useful oxazolidinones.
    Type: Grant
    Filed: January 15, 2002
    Date of Patent: December 10, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventor: Bruce Allen Pearlman
  • Quinuclidine-substituted aryl compounds for treatment of disease
    Patent number: 6486172
    Abstract: The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which &agr;7 is known to be involved.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: November 26, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Jason K. Myers, Vincent E. Groppi, Jr., David W. Piotrowski
  • Anti-bacterial methods and materials
    Patent number: 6485899
    Abstract: Staphylococcus aureus virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel S. aureus mutants useful in vaccines.
    Type: Grant
    Filed: March 16, 2000
    Date of Patent: November 26, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: David Holden, Ji Min Mei
  • Inhibitors of &agr;4&bgr;1 mediated cell adhesion
    Patent number: 6482849
    Abstract: The present invention relates to small molecules according to the formula [I]: which are potent inhibitors of &agr;4&bgr;1 mediated adhesion to either VCAM or CS-1 and which can be used for treating or preventing &agr;4&bgr;1 adhesion mediated conditions in a mammal such as a human.
    Type: Grant
    Filed: June 23, 1998
    Date of Patent: November 19, 2002
    Assignees: Tanabe Seiyaku Co., Ltd., Pharmacia & Upjohn Company
    Inventors: Thomas J. Lobl, Bradley R. Teegarden, Alexander Polinsky, Gilbert M. Rishton, Masafumi Yamagishi, Steven Tanis, Jed F. Fisher, Edward W. Thomas, Robert A. Chrusciel
  • Matrix metalloproteinase inhibitors
    Patent number: 6482827
    Abstract: A compound, which is an amine derivative of formula (I) wherein W is —CNHOH or —COOH: R1 and R2 are each hydrogen or an organic residue, R3 is an organic group, Q is a secondary or tertiary acyclic or cyclic amido group, and the pharmaceutically acceptable salts, solvates and hydrates thereof, are inhibitors of matrix metalloproteinases (MMPs) and of the release of tumor necrosis factor-alpha (TNF) from cells. They are therefore useful in the prevention, control and treatment of diseases in which MMPs or TNF are involved, especially tumoral and inflammatory diseases. Processes for their preparation and pharmaceutical compositions containing them are also described.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: November 19, 2002
    Assignee: Pharmacia & Upjohn S.p.A.
    Inventors: Marco Alpegiani, Pierluigi Bissolino, Francesca Abrate, Ettore Perrone, Riccardo Corigli, Daniela Jabes
  • Oxazolidinone compounds and methods of preparation and use thereof
    Publication number: 20020169191
    Abstract: Oxazolidinones and methods for their synthesis are provided. Further provided are methods of making biologically active oxazolidinones as well as pharmaceutically acceptable compositions comprising the oxazolidinones. Oxazolidinones as disclosed herein can be readily synthesized and used in a variety of applications including use as antimicrobial agents. In one embodiment, a variety of thioamidomethyloxazolidinones and methods for their synthesis and use are provided.
    Type: Application
    Filed: June 27, 2002
    Publication date: November 14, 2002
    Applicant: PHARMACIA & UPJOHN COMPANY
    Inventors: Mikhail F. Gordeev, Gary W. Luehr, Dinesh V. Patel, Robert C. Gadwood
  • Quinuclidine-substituted aryl compounds for treatment of disease
    Patent number: 6479510
    Abstract: The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which &agr;7 is known to be involved.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: November 12, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Jason K. Myers, Vincent E. Groppi, Jr., David W. Piotrowski